WVE
Wave Life SciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
WVE vs peer average
25/100
WVE vs. peer average (D vs. B)
Grade spread
A 3 · B 2 · C 2 · D 1 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
AMGN is the first available peer comparator.
Amgen is not a direct platform peer, but it is a useful obesity benchmark because Wave is trying to argue differentiated body composition benefits in a market dominated by better-capitalized metabolic players. The comparison highlights how early and fragile WVE-007 still is versus obesity programs with more mature development and commercialization infrastructure.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
WVE
Wave Life Sciences
AMGN
Amgen
Grade
D
C
Momentum
3
36
Value
41
64
Sentiment
83
47
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Defensive
Mixed
Grade position vs AMGN
WVE / AMGN
Grade Position
Below peers
WVE vs. peer average (D vs. B)
25/100
Momentum
3
AMGNValue
41
AMGNSentiment
83
WVERotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs WVE
AMGN is the first peer returned for this comparison set.